The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Tecartus



Kite Pharma EU B.V.EU/1/20/1492/001

Main Information

Trade NameTecartus
Active SubstancesAutologous Peripheral Blood T Cells CD4 and CD8 selected and CD3 and CD28 Activated Transduced with Retroviral
Dosage FormDispersion for infusion
Licence HolderKite Pharma EU B.V.
Licence NumberEU/1/20/1492/001

Group Information

ATC CodeL01X OTHER ANTINEOPLASTIC AGENTS

Status

License statusAuthorised
Licence Issued14/12/2020
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website

Educational Materials - HCP

Educational Materials - Patient

« Back